|
Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer
RECRUITINGPhase 3Sponsored by Medical University of Bialystok
Actively Recruiting
PhasePhase 3
SponsorMedical University of Bialystok
Started2022-11-01
Est. completion2028-01-31
Eligibility
Age18 Years – 45 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05468554
Summary
This study is aimed to investigate the metformin effect on the fertility of women treated with 131 I for thyroid cancer
Eligibility
Age: 18 Years – 45 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria: 1. Female subjects in reproductive age \>18 \<45 years. 2. Subjects with diagnosed papillary thyroid carcinoma with various pathological stage TNM (I-II). 3. Subjects not treated with 131I 4. Willingness to comply with protocol procedures. Exclusion Criteria: 1. Hypersensitivity to metformin. 2. Subjects with polycystic ovarian syndrome or other diseases of the ovaries (primary / secondary ovarian failure). 3. Subjects taking metformin during last week. 4. Subjects with liver malfunction and abnormal hepatitis marker results (ALT and AST activity \>3ULN.\* 5. Subjects with eGFR below 45ml/min/1.73m2.\* 6. Subjects with lactic acidosis or having history of metabolic acidosis. 7. Subjects with serum AMH concentration\* below lower range norm. 8. Subjects with history of congestive heart disease NYHA stage III/IV. 9. Subjects with acute myocardial ischemia (CCS 3-4). 10. Subjects with history of sepsis or severe infection. 11. Subject with lung disease (uncontrolled asthma based on GINA 2000 Guidelines and COPD GOLD ≥ 3 stage). 12. Positive result of pregnancy test or pregnancy planned during the study. 13. Alcohol or other substance dependent syndromes. 14. BMI \<18.5 kg/m2. 15. Accompanying diseases with poor prognosis in the opinion of the researcher. 16. As per Investigator (or his designee) judgement, subject cannot participate in the study due to reasons (i.e. medical, psychiatric and/or social reason). 17. Unreliability or lack of cooperation. \*based on the laboratory results from screening visit
Conditions2
CancerThyroid Cancer
Interventions1
Related trials
- A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis — The Hospital for Sick Children
- A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes — Boryung Pharmaceutical Co., Ltd
- Acupuncture or Metformin for Insulin Resistance in Women With PCOS — Karolinska Institutet
- Acute Portal Pressure Reduction by Metformin and Carvedilol Compared to Carvedilol Alone in Cirrhosis. — Institute of Liver and Biliary Sciences, India
- Anti-Diabetic Drug, Exercise and Healthy Diet for Knee Osteoarthritis With Overweight/Obesity — The University of Hong Kong
- Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes — National Institute of Cardiology, Warsaw, Poland
- Comparison of Metformin Versus Glyburide for Blood Sugar Control in Women With Gestational Diabetes — Nishtar Medical University
- Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI) — University Of Nigeria Teaching Hospital
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorMedical University of Bialystok
Started2022-11-01
Est. completion2028-01-31
Eligibility
Age18 Years – 45 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05468554